Healthpeak Properties, Inc. (DOC)
(Delayed Data from NYSE)
$18.80 USD
+0.46 (2.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.82 +0.02 (0.11%) 6:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
DOC 18.80 +0.46(2.51%)
Will DOC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DOC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DOC
Healthpeak's (DOC) Q1 FFO Beat Estimates, Same-Store NOI Up
Healthpeak (DOC) Q1 FFO and Revenues Surpass Estimates
DOC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alexandria (ARE) Beats Q1 AFFO Estimates, Narrows '24 Guidance
What's in the Cards for Healthpeak (DOC) This Earnings Season?
Should Investors Retain Healthpeak (DOC) Stock for Now?
Other News for DOC
Healthpeak Properties, Inc. (DOC) Q1 2024 Earnings Call Transcript
DOC Crosses Above Key Moving Average Level
Healthpeak Properties upgraded at Exane BNP Paribas after guidance boost
Exane BNP Paribas gets more bullish on Healthpeak Properties, upgrades shares
Scotiabank Sticks to Their Buy Rating for Healthpeak Properties (DOC)